The Study
Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
This study looked at people with diabetes who got two different kinds of shots and saw who had fewer heart problems. It didn't randomly assign who got which shot, so we can't say one shot definitely caused the better results — maybe the people who got one shot were just healthier to begin with.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Doctors give two kinds of shots to people with type 2 diabetes when pills aren't enough: one is GLP-1RA, the other is basal insulin. This study looked at which one is safer for the heart.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 566 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — for every 100 people on basal insulin, about 43 had a serious heart problem or died in 2 years; for those on GLP-1RA, only about 26 did.
- 2That’s like preventing 17 serious events per 100 people.
- 3People who got GLP-1RA had 41% fewer heart attacks, strokes, or deaths than those who got basal insulin.
- 4They also had 44% fewer severe low blood sugar episodes.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cardiovascular Diabetology
Year
2021
Authors
Enrico Longato, Barbara Di Camillo, G. Sparacino, Lara Tramontan, A. Avogaro, G. Fadini
Related Content
Claims (5)
GLP-1 receptor agonists improve heart and metabolic health in people with type 2 diabetes and prediabetes through direct actions on GLP-1 receptors, without relying on weight loss or the body's natural incretin signals.
Among adults with type 2 diabetes who start injectable treatment, those who begin a GLP-1 receptor agonist have a 41% lower risk of dying from any cause and a 41% lower risk of having a stroke over two years compared to those who start basal insulin, based on observed data adjusted for other health factors.
Among adults with type 2 diabetes starting injectable treatment, those using GLP-1 receptor agonists had a lower risk of heart attack, stroke, or death over two years compared to those using basal insulin, based on statistical analysis of patient data.
In adults with type 2 diabetes who start injectable diabetes medication, those using GLP-1 receptor agonists have a lower risk of having a heart attack or being hospitalized for heart failure compared to those using basal insulin, over a period of about two years, regardless of whether they had prior heart disease.
For adults with type 2 diabetes starting injectable treatment, GLP-1 receptor agonists are linked to a 44% lower risk of severe low blood sugar episodes compared to basal insulin over two years.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.